Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss H Arita, Y Narita, S Fukushima, K Tateishi, Y Matsushita, A Yoshida, ... Acta neuropathologica 126, 267-276, 2013 | 406 | 2013 |
STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors A Yoshida, K Tsuta, M Ohno, M Yoshida, Y Narita, A Kawai, H Asamura, ... The American journal of surgical pathology 38 (4), 552-559, 2014 | 389 | 2014 |
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas H Arita, K Yamasaki, Y Matsushita, T Nakamura, A Shimokawa, H Takami, ... Acta neuropathologica communications 4, 1-14, 2016 | 241 | 2016 |
Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas T Nakamura, K Tateishi, T Niwa, Y Matsushita, K Tamura, M Kinoshita, ... Neuropathology and applied neurobiology 42 (3), 279-290, 2016 | 215 | 2016 |
Revisiting TP53 Mutations and Immunohistochemistry—A Comparative Study in 157 Diffuse Gliomas H Takami, A Yoshida, S Fukushima, H Arita, Y Matsushita, T Nakamura, ... Brain pathology 25 (3), 256-265, 2015 | 164 | 2015 |
IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy Y Okita, Y Narita, Y Miyakita, M Ohno, Y Matsushita, S Fukushima, M Sumi, ... International journal of oncology 41 (4), 1325-1336, 2012 | 88 | 2012 |
TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas H Arita, Y Narita, H Takami, S Fukushima, Y Matsushita, A Yoshida, ... Acta neuropathologica 126, 939-941, 2013 | 79 | 2013 |
Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas H Arita, Y Narita, Y Matsushita, S Fukushima, A Yoshida, H Takami, ... Brain tumor pathology 32, 22-30, 2015 | 75 | 2015 |
Multinodular and vacuolating neuronal tumor of the cerebrum S Fukushima, A Yoshida, Y Narita, H Arita, M Ohno, Y Miyakita, ... Brain Tumor Pathology 32, 131-136, 2015 | 50 | 2015 |
Long-term follow-up of vanishing tumors in the brain: how should a lesion mimicking primary CNS lymphoma be managed? Y Okita, Y Narita, Y Miyakita, M Ohno, S Fukushima, A Maeshima, ... Clinical neurology and neurosurgery 114 (9), 1217-1221, 2012 | 45 | 2012 |
Assessment of the diagnostic utility of serum MicroRNA classification in patients with diffuse glioma M Ohno, J Matsuzaki, J Kawauchi, Y Aoki, J Miura, S Takizawa, K Kato, ... JAMA network open 2 (12), e1916953-e1916953, 2019 | 41 | 2019 |
Clinical presentation of anaplastic large‑cell lymphoma in the central nervous system M Nomura, Y Narita, Y Miyakita, M Ohno, S Fukushima, T Maruyama, ... Molecular and clinical oncology 1 (4), 655-660, 2013 | 41 | 2013 |
Brain metastasis-related microRNAs in patients with advanced breast cancer J Sato, A Shimomura, J Kawauchi, J Matsuzaki, Y Yamamoto, S Takizawa, ... Plos one 14 (10), e0221538, 2019 | 38 | 2019 |
TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations H Arita, Y Matsushita, R Machida, K Yamasaki, N Hata, M Ohno, ... Acta neuropathologica communications 8, 1-11, 2020 | 34 | 2020 |
Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma K Satomi, M Ohno, Y Matsushita, M Takahashi, Y Miyakita, Y Narita, ... Modern Pathology 34 (4), 688-700, 2021 | 33 | 2021 |
Risk factors for early death after surgery in patients with brain metastases: reevaluation of the indications for and role of surgery H Arita, Y Narita, Y Miyakita, M Ohno, M Sumi, S Shibui Journal of neuro-oncology 116, 145-152, 2014 | 32 | 2014 |
Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas T Yamauchi, M Ohno, Y Matsushita, M Takahashi, Y Miyakita, Y Kitagawa, ... Brain tumor pathology 35, 148-158, 2018 | 29 | 2018 |
A case of more than 20 years survival with glioblastoma, and development of cavernous angioma as a delayed complication of radiotherapy S Fukushima, Y Narita, Y Miyakita, M Ohno, T Takizawa, Y Takusagawa, ... Neuropathology 33 (5), 576-581, 2013 | 28 | 2013 |
Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas M Ohno, Y Narita, Y Miyakita, Y Matsushita, A Yoshida, S Fukushima, ... Brain tumor pathology 30, 224-232, 2013 | 27 | 2013 |
Pathological findings and prognostic factors in recurrent glioblastomas Y Okita, Y Narita, Y Miyakita, M Ohno, S Fukushima, T Kayama, S Shibui Brain tumor pathology 29, 192-200, 2012 | 26 | 2012 |